A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee
Latest Information Update: 03 Nov 2026
At a glance
- Drugs LEVI 04 (Primary)
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- Sponsors Levicept
Most Recent Events
- 22 Oct 2026 According to aLevicept media release, data from the rial will be presented at International Association for the Study of Pain, IASP World Congress on Pain 2026 (Bangkok, 26-30 October) and American College of Rheumatology, annual ACR Convergence 2026 (Orlando, 6-11 November).
- 02 Sep 2026 According to a Levicept media release, results from this trial presented at the European Alliance of Associations for Rheumatology (EULAR) conference.
- 03 Jun 2026 According to Levicept media release, will present key data from its Phase II study of LEVI-04 in patients with pain and disability due to OA of the knee at the European Alliance of Associations for Rheumatology (EULAR) conference being held in London from 3 to 6 June.